Literature DB >> 8388744

The protein tyrosine kinase, fyn, in Alzheimer's disease pathology.

S K Shirazi1, J G Wood.   

Abstract

Immunohistochemistry was used to assess the distribution of protein tyrosine kinases in Alzheimer's disease (AD) pathology. One of these, fyn, exhibited an interesting pattern of immunoreactivity. Low levels of immunoreactivity were apparent in neurons from both normal and AD brain. However a subset of neurons in AD brain exhibited intense fyn immunoreactivity. Double label immunohistochemistry revealed that fyn-positive neurons were also positive for abnormally phosphorylated microtubule-associated protein, tau. Proline-directed kinases, whose activity is regulated by phosphorylation on tyrosine, may be responsible for abnormal tau phosphorylation. These results identify fyn as a candidate kinase for regulating putative proline-directed kinases involved in abnormal tau phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388744     DOI: 10.1097/00001756-199304000-00024

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  41 in total

1.  Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases.

Authors:  Ritchie Williamson; Timothy Scales; Bruce R Clark; Graham Gibb; C Hugh Reynolds; Stuart Kellie; Ian N Bird; Ian M Varndell; Paul W Sheppard; Ian Everall; Brian H Anderton
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

2.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 3.  Protein phosphatases and Alzheimer's disease.

Authors:  Steven P Braithwaite; Jeffry B Stock; Paul J Lombroso; Angus C Nairn
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 4.  Targeting Fyn Kinase in Alzheimer's Disease.

Authors:  Haakon B Nygaard
Journal:  Biol Psychiatry       Date:  2017-06-13       Impact factor: 13.382

Review 5.  Tau Proteins and Tauopathies in Alzheimer's Disease.

Authors:  Fong Ping Chong; Khuen Yen Ng; Rhun Yian Koh; Soi Moi Chye
Journal:  Cell Mol Neurobiol       Date:  2018-01-03       Impact factor: 5.046

6.  Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice.

Authors:  S Sakura Minami; Thomas G Clifford; Hyang-Sook Hoe; Yasuji Matsuoka; G William Rebeck
Journal:  Neurobiol Aging       Date:  2011-07-07       Impact factor: 4.673

7.  Measurement of dissociation rate of biomolecular complexes using CE.

Authors:  Peilin Yang; Yingwei Mao; Angel W-M Lee; Robert T Kennedy
Journal:  Electrophoresis       Date:  2009-02       Impact factor: 3.535

8.  Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model.

Authors:  Frédéric Calon; Giselle P Lim; Fusheng Yang; Takashi Morihara; Bruce Teter; Oliver Ubeda; Phillippe Rostaing; Antoine Triller; Norman Salem; Karen H Ashe; Sally A Frautschy; Greg M Cole
Journal:  Neuron       Date:  2004-09-02       Impact factor: 17.173

9.  Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.

Authors:  C Vergara; L Ordóñez-Gutiérrez; F Wandosell; I Ferrer; J A del Río; R Gavín
Journal:  Mol Neurobiol       Date:  2014-06-26       Impact factor: 5.590

Review 10.  Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy.

Authors:  L W Jin; T Saitoh
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.